The aim of this technology assessment, which has been commissioned by NICE through the NIHR SR Programme as part of the NICE’s Single Technology Appraisal process, is to review the submission received from Merck KGaA/Pfizer on the clinical and cost-effectiveness of Avelumab (Bavencio®) for the maintance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy. The main source of evidence submitted by Merck KGaA/Pfizer, consists of a Phase III, multicentre, open-label RCT (JAVELIN Bladder 100). The Aberdeen HTA Group acts as the Evidence Review Group (ERG) for this technology appraisal and provides an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from Merck KGaA/Pfizer and the ERG’s critique, NICE will release appropriate clinical guidance.
For more information see: https://www.nice.org.uk/guidance/indevelopment/gid-ta10624
Miriam Brazzelli; firstname.lastname@example.org